This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Decitabine). Patients in experimental group will receive hUC-MSC, while control group receive placebo (normal saline), four weeks as a course of treatment. All of the patients accept examination before treatment, including~diagnostic projects: bone marrow test, peripheral blood classification, chromosome, and MDS fusion gene test, etc.;~routine examination: blood, urine, and stool routine test, X-ray film in chest, electrocardiogram, etc.;~stem cell-based medicinal products usage, dosage, time, and course of treatment.~Then, patients will accept routine examination everyday, and after treatment, investigator will follow-up for 6 months, to evaluate the security and efficacy of hUC-MSC.
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.